Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. Reply
N Engl J Med
.
2024 Oct 24;391(16):1555-1556.
doi: 10.1056/NEJMc2411471.
Authors
Shun Lu
1
,
Suresh S Ramalingam
2
Affiliations
1
Shanghai Jiao Tong University School of Medicine, Shanghai, China.
2
Emory University School of Medicine, Atlanta, GA ssramal@emory.edu.
PMID:
39442050
DOI:
10.1056/NEJMc2411471
No abstract available
Publication types
Letter
Comment